{"id":"NCT02209324","sponsor":"Maruho Co., Ltd.","briefTitle":"Open-label Study of ASP2151 in Herpes Simplex Patients","officialTitle":"Open-label Study of ASP2151 in Herpes Simplex Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2015-07","completion":"2015-08-20","firstPosted":"2014-08-05","resultsPosted":"2024-09-27","lastUpdate":"2024-09-27"},"enrollment":275,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Herpes Simplex"],"interventions":[{"type":"DRUG","name":"ASP2151","otherNames":["200 mg once daily"]}],"arms":[{"label":"ASP2151","type":"EXPERIMENTAL"}],"summary":"A multicenter, open-label study is conducted to evaluate the efficacy and safety of ASP2151 in patients with herpes simplex (recurrent labial/facial herpes and recurrent genital herpes and Kaposi varicelliform).","primaryOutcome":{"measure":"Percentage of Participants With Healing by Day 8","timeFrame":"8 days","effectByArm":[{"arm":"ASP2151","deltaMin":194,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":3,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":271},"commonTop":["Fibrin degradation products increased","Alpha 1 microglobulin increased","Nasopharyngitis","Stomatitis","Folliculitis"]}}